164 related articles for article (PubMed ID: 32040959)
1. Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.
Lévy Y; Lelièvre JD; Assoumou L; Aznar E; Pulido F; Tambussi G; Crespo M; Meybeck A; Molina JM; Delaugerre C; Izopet J; Peytavin G; Cardon F; Diallo A; Lancar R; Béniguel L; Costagliola D
Ann Intern Med; 2020 Mar; 172(5):297-305. PubMed ID: 32040959
[TBL] [Abstract][Full Text] [Related]
2. Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
[TBL] [Abstract][Full Text] [Related]
3. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
[TBL] [Abstract][Full Text] [Related]
5. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
7. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
Molina JM; Grund B; Gordin F; Williams I; Schechter M; Losso M; Law M; Ekong E; Mwelase N; Skoutelis A; Wiselka MJ; Vandekerckhove L; Benfield T; Munroe D; Lundgren JD; Neaton JD;
Lancet HIV; 2018 Apr; 5(4):e172-e180. PubMed ID: 29352723
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
[TBL] [Abstract][Full Text] [Related]
9. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
[TBL] [Abstract][Full Text] [Related]
11. Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial.
Sierra-Madero JG; Ellenberg SS; Rassool MS; Tierney A; Belaunzarán-Zamudio PF; López-Martínez A; Piñeirúa-Menéndez A; Montaner LJ; Azzoni L; Benítez CR; Sereti I; Andrade-Villanueva J; Mosqueda-Gómez JL; Rodriguez B; Sanne I; Lederman MM;
Lancet HIV; 2014 Nov; 1(2):e60-7. PubMed ID: 26423989
[TBL] [Abstract][Full Text] [Related]
12. High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C.
Pujari S; Gaikwad S; Bele V; Joshi K; Dabhade D
J Int Assoc Provid AIDS Care; 2018; 17():2325958218759211. PubMed ID: 29473485
[TBL] [Abstract][Full Text] [Related]
13. Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
Rockstroh JK; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Zhang-Roper R; Wang R; Pineda JA; Heera J
Antivir Ther; 2017; 22(3):263-269. PubMed ID: 27924779
[TBL] [Abstract][Full Text] [Related]
14. A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues.
Manfredi R; Calza L; Marinacci G; Cascavilla A; Colangeli V; Salvadori C; Martelli G; Appolloni L; Puggioli C; Viale P
Infez Med; 2015 Mar; 23(1):36-43. PubMed ID: 25819049
[TBL] [Abstract][Full Text] [Related]
15. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
Stellbrink HJ; Le Fevre E; Carr A; Saag MS; Mukwaya G; Nozza S; Valluri SR; Vourvahis M; Rinehart AR; McFadyen L; Fichtenbaum C; Clark A; Craig C; Fang AF; Heera J
AIDS; 2016 May; 30(8):1229-38. PubMed ID: 26854810
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
[TBL] [Abstract][Full Text] [Related]
17. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-term maraviroc use in a heterogeneous group of HIV-infected patients: A retrospective cohort study.
Weehuizen JM; Wensing AMJ; Mudrikova T; Wit FWNM; Hoepelman AIM
Int J Antimicrob Agents; 2019 Aug; 54(2):215-222. PubMed ID: 30831236
[TBL] [Abstract][Full Text] [Related]
19. [Maraviroc efficacy in clinical studies on the development of the molecule].
Moreno S; Hernández B; Gutiérrez C; Delsol E
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():17-22. PubMed ID: 19133217
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
